Fenbufen

HCID 3335CAS 36330-85-5
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

Standard-SMILES
O=C(O)CCC(=O)c1ccc(-c2ccccc2)cc1
InChIKey
ZPAKPRAICRBAOD-UHFFFAOYSA-N
Summenformel
C16H14O3
Durchschnittliche Molmasse
254,28 g/mol
Monoisotopische Masse
254,09429431

Überblick

Fenbufen is a member of biphenyls and a 4-oxo monocarboxylic acid. It has a role as a non-steroidal anti-inflammatory drug.

Namen und Bezeichner

Bevorzugter Name
Fenbufen
IUPAC
4-oxo-4-(4-phenylphenyl)butanoic acid
Lokaler Name
Fenbufen
Englischer Name
Fenbufen
Summenformel
C16H14O3
Molmasse
254.29

Namen und Synonyme

fenbufen36330-85-54-(4-Biphenylyl)-4-oxobutyric acid3-(4-Biphenylylcarbonyl)propionic acid3-(4-Phenylbenzoyl)propionic acidFenbufene4-(biphenyl-4-yl)-4-oxobutanoic acidFenbufenumgamma-Oxo(1,1'-biphenyl)-4-butanoic acidCL-822043-(4-Biphenylcarbonyl)propionic acidDTXSID9023043
Weitere Namen anzeigen
4-([1,1'-Biphenyl]-4-yl)-4-oxobutanoic acidbufemidcl82204napanolcinopalCinopolenbufenlederfenFenbufen CRS
NSC-757812CL 82,2049815R1WR9B(1,1'-BIPHENYL)-4-BUTANOIC ACID, gamma-OXO-DTXCID703043CHEBI:315994-[1,1'-biphenyl-4-yl]-4-oxobutanoic acid4-(1,1'-biphenyl-4-yl)-4-oxobutanoic acid

Datenbank-Bezeichner

CAS
36330-85-5
PubChem CID
3335
DTXSID
DTXSID9023043
ChEMBL
CHEMBL277522
ChEBI
CHEBI:31599
UNII
9815R1WR9B
EC Number
252-979-0
Nikkaji
J3.182H

Eigenschaften

Berechnete Struktureigenschaften

XLogP
3,2
Polarare Oberfläche (TPSA)
54,4 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
5
Schwere Atome
19

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
LogP2.91
Human DrugsPharmaceuticals
Melting Point185-187
Collision Cross Section150.36 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
184 · 184-187 °C (lit.)
Siedepunkt
357.5 °C · 357.5°C (rough estimate)
Dichte
1.1565 · 1.1565 (rough estimate)
Brechungsindex
1.56 · 1.5600 (estimate)
storage temp.
2 · 2-8°C
Löslichkeit
Very slightly soluble in water, slightly soluble in acetone, in ethanol (96 per cent) and in methylene chloride.

Sicherheit und Regulatorisches

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 42 reports by companies from 2 notifications to the ECHA C&L Inventory.

Gefahrenhinweise

Other Safety InformationIMAP assessments - [1,1'-Biphenyl]-4-butanoic acid, .gamma.-oxo-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 3 (100%)

Sicherheitsdaten

wgk
3
ridadr
UN 2811 6.1/PG 3
hs_code
2918300090
RTECS-Nr.
DV1761000
risk_code
25
Toxizität
LD50 in various strains of mice, rats (mg/kg): 795-1673, 200-720 orally; 506-811, 265-575 i.p. (Bolte)

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

M - Musculo-skeletal system

QM - Musculo-skeletal system

MeSH Pharmacological Classification · 2 Einträge

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.

Verwendung und Herstellung

Use ClassificationPharmaceuticals
Anwendungen · 2 Einträge

BeschreibungFenbufen has been found to be an effective, well-tolerated drug for the treatment of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Fenbufen is prepared by the Friedel-Crafts (aluminum chloride – nitrobenzene) acylation of biphenyl with succinic anhydride. The compound is metabolized in humans first to 4-hydroxy-4-biphenylbutyric acid (tmax 2.5 h) then to 4-biphenyl acetic acid (tmax 7.5 h). Both metabolites are more active than fenbufen itself and circulate for several hours (t1/2 10 h). This slow conversion of fenbufen to active metabolites having relatively long plasma half-lives allows for once a day dosing with this agent.

VerwendenCyclo-oxygenase inhibitor; analgesic; anti-inflammatory

Vor- und nachgelagerte Produkte

Nachgelagerte Produkte

Anbieter50 Anbieter

上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]
上海策嵘生物科技有限公司[email protected]
HubeiwidelychemicaltechnologyCo.,Ltd18627774460 · [email protected]
合肥翰刚医药科技有限公司+8618062405514 · [email protected]
温州共赢化学有限公司+86-0086-577-64498589 +86-15355981851 · [email protected]

Zugehörige Reaktionen

15
Reaktionsaufzeichnung erstellen

Verknüpfte Notizen

Wird geladen…